13 / 15
Note:
June 24-25, 2019 | Philadelphia, USA
Mental Health 2019
Journal of Mental Health and Aging | Volume 3
Page 24
PSYCHIATRY DISORDERS, MENTAL
HEALTH ANDWELLNESS
World Summit on
OF EXCELLENCE
IN INTERNATIONAL
MEETINGS
alliedacademies.comYEARS
TRANSCRANIAL MAGNETIC STIMULATION FOR OBSESSIVE COMPULSIVE DISORDER
Aron Tendler
Advanced Mental Health Care Inc- Brainsway, USA
O
bsessive-compulsive disorder (OCD) is a chronic disabling condition with a lifetime prevalence of 2.3%. 1 in
40 adults are currently living with symptoms of OCD, making it the fourth most common neuropsychiatric
illness and the fifth leading cause of disease burden ages 15-22 in the developed world. The presentation will
briefly review pharmacologic and psychotherapeutic treatments for OCD. The neuroanatomy of OCD will be
reviewed as a basis for neuromodulatory interventions, both invasive and non-invasive. An overview of neu-
romodulatory interventions for OCD will be presented DBS, rTMS, DTMS, TDCS. Details of FDA approved DTMS
technology followed by a detailed presentation of the pilot, multi-center randomized sham controlled and
open label efficacy and safety dataof the H7/HAC DTMS OCD system. How to tailor provocations to the patient’s
symptoms before the stimulation (Cognitive paired association) with examples will be given. The lecture will
conclude with a discussion on when to implement the neuromodulation treatments in the treatment pathway
and future research directions for DTMS with OCD.
Aron Tendler received his MD from State University of NY Downstate Medical Center with a distinction in research. He completed
a residency in Psychiatry at the University of Chicago. He is Board certified in Psychiatry and Sleep Medicine. He is the author of
numerous peer reviewed publications. He is the co-founder of Advanced Mental Health Care Inc., a clinical and research center with
three sites in South Florida, USA and the Chief Medical Officer for Brainsway Ltd., a medical device manufacturer. He has been the
PI on multiple multicenter clinical trials, leading to device approvals for major depression and obsessive compulsive disorder. He
spends half his time in clinical practice and half his time on education and research.
aron.tendler@gmail.comBIOGRAPHY
Aron Tendler, J Ment Health Aging 2019, Volume 3